Clinical trials: Newly Diagnosed Breast Cancer
Breast Carcinoma, Metastatic Breast Cancer
Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases
- Conditions
- Breast Carcinoma, Metastatic Breast Cancer, Invasive Breast Cancer, Distant Metastases.Pathology
- Trial name
- NCT03970967
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Russia
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Newly Diagnosed Breast Cancer
A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients
The purpose of this study is to provide the physicians with quality long term follow up data on subjects from the Breast Cancer Clinic and the Plastic Surgery Clinic who have been newly diagnosed with breast cancer and will…
- Trial name
- NCT01176838
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University
Breast Cancer Females
The Effect of Group and Mobile Wellness Coaching Given to Women With Breast Cancer on the Disease
It is believed that this study will serve as a model for a Wellness Coaching program delivered to patients newly diagnosed with breast cancer via a mobile application and contribute to the literature.
- Trial name
- NCT07364760
- Testing
- Wellness coaching program with mobile application, Group Wellness Coaching Program, Mobile app and group wellness coaching program
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Breast Cancer
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
The combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant (given before surgery) treatment for patients that have either inoperable or operable breast cancer.
- Trial name
- NCT00656669
- Testing
- sunitinib alone, sunitinib plus paclitaxel, doxorubicin and cyclophosphamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Indiana University
Stage I Breast Cancer, Stage II Breast Cancer
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue.
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer
- Trial name
- NCT01194427
- Testing
- Vorinostat and Tamoxifen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer
The goal of the study is to assess the safety and effectiveness of the combination of anti-PD1 immunotherapy (pembrolizumab) and radiotherapy in the preoperative treatment of HER2-negative breast cancer resistant to classical…
- Trial name
- BREAST-BOOSTER (NCT06472583)
- Testing
- Keytruda, Preoperative radiation therapy
- Where
- Poland
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Breast Cancer
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
- Trial name
- NCT04158258
- Testing
- Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine
- Where
- 30 sites in Argentina, Brazil and 8 more
- Volunteers
- 2,907 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Symptom, Behavioral
YES Study - Newly Diagnosed/Metastatic Intervention
This research study is being done to monitor common symptoms and behavior, and to provide supportive care information and peer support, as well as research opportunities for young women ages of 18-39 years old who have been…
- Trial name
- YES (NCT04379414)
- Testing
- YES portal
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasm
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
The purpose of this study is to determine whether a multimodal program based on therapeutic exercise and vagal activation techniques for newly diagnosed breast cancer women has better results in terms of neurotoxicity prevenion…
- Trial name
- ATENTO (NCT04583124)
- Testing
- ATENTO-B, ATENTO-T
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Universidad de Granada
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
This phase II trial tests whether panitumumab and pembrolizumab in combination with standard of care chemotherapy before surgery (neoadjuvant) works to shrink tumors in patients with stage III-IV triple negative breast cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT05177796
- Testing
- Carboplatin, Cyclophosphamide, Doxorubicin
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
RATIONALE: Alemtuzumab and glucocorticoids, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00410657
- Testing
- alemtuzumab, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Breast Cancer Surgery
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
The purpose of the study is to determine the optimal, lowest dose of radioactive tracer required for Positron Emission Mammography (PEM), and the accuracy and reliability of PEM in pre-surgical evaluations for patients with newly…
- Trial name
- NCT01241721
- Testing
- Positron Emission Mammography (PEM)
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Swedish Medical Center
Breast Cancer
Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer
RATIONALE: Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00766454
- Testing
- DNA analysis, mutation analysis, polymorphism analysis
- Where
- United States
- Volunteers
- 1,104 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Neuropathy
Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy
Feasibility study to examine the preventative ability of massage therapy on paclitaxel induced peripheral neuropathy in breast cancer
- Conditions
- Breast Cancer, Neuropathy, Neuropathy;Peripheral
- Trial name
- PIPN (NCT03557554)
- Testing
- Massage
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Bryan Schneider
Breast Cancer Stage IV
Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases
Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases
- Trial name
- TUXEDO-1 (NCT04752059)
- Testing
- Trastuzumab deruxtecan
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University of Vienna
Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
This randomized phase II trial is studying 4-hydroxytamoxifen to see how well it works compared with tamoxifen citrate in treating women with newly diagnosed ductal breast carcinoma in situ.
- Trial name
- NCT00952731
- Testing
- afimoxifene, tamoxifen citrate
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Breast Cancer
FES BPET-DBT in Newly Diagnosed Breast Cancer
Patients with newly diagnosed primary estrogen-receptor (ER) positive breast cancer, with at least one breast lesion that is 1.0 cm in diameter or greater, may be eligible for this study.
- Trial name
- NCT05659797
- Testing
- BPET/DBT imaging, 18F-FES
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer
RATIONALE: Studying samples of urine in the laboratory from women with breast cancer may help doctors learn whether tamoxifen and aromatase inhibitors alter the metabolism of estrogens.
- Trial name
- NCT00569543
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Nebraska
Stage IA Breast Cancer, Stage IB Breast Cancer
Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy
This pilot clinical trial studies a health education intervention in reducing weight gain in patients with newly diagnosed stage I-IV breast cancer undergoing chemotherapy.
- Conditions
- Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01941784
- Testing
- educational intervention, counseling intervention, telephone-based intervention
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences